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Introduction: Extracellular matrix protein 1 (ECM1) is a secreted glycoprotein with putative functions in cell
proliferation, angiogenesis and differentiation. Expression of ECM1 in several types of carcinoma suggests that it
may promote tumor development. In this study, we investigated the role of ECM1 in oncogenic cell signaling in
breast cancer, and potential mechanisms for its effects.
Methods: In order to find out the functional role of ECM1, we used the recombinant human ECM1 and viral
transduction systems which stably regulated the expression level of ECM1. We examined the effect of ECM1 on cell
proliferation and cell signaling in vitro and in vivo. Moreover, tissues and sera of patients with breast cancer were
used to confirm the effect of ECM1.
Results: ECM1 protein was increased in trastuzumab-resistant (TR) cells, in association with trastuzumab resistance
and cell proliferation. Through physical interaction with epidermal growth factor receptor (EGFR), ECM1 potentiated
the phosphorylation of EGFR and extracellular signal-regulated kinase upon EGF treatment. Moreover, ECM1-
induced galectin-3 cleavage through upregulation of matrix metalloproteinase 9 not only improved mucin 1
expression, but also increased EGFR and human epidermal growth factor receptor 3 protein stability as a
secondary signaling.
Conclusions: ECM1 has important roles in both cancer development and trastuzumab resistance in breast cancer
through activation of EGFR signaling.Introduction
Extracellular matrix protein 1 (ECM1) is a glycosylated
protein, secreted extracellularly, that was first identified in
osteogenic stromal cells [1]. The physiological function of
ECM1 was first reported in keratinocytes, in which the
gene was mapped to chromosome 1q21 near the epider-
mal differentiation complex and shown to express ECM1a
and ECM1b by differentiation-dependent alternative spli-
cing [2]. Recombinant ECM1 promotes endothelial cell
proliferation and blood vessel formation, suggesting a
functional role in angiogenesis [3]. Mutation in ECM1* Correspondence: incheol@hanyang.ac.kr
1Department of Life Science, Hanyang University, 222 Wangshimni-ro, Seoul
133-791, Republic of Korea
6Natural Science Institute, Hanyang University, 222 Wangshimni-ro, Seoul
133-791, Republic of Korea
Full list of author information is available at the end of the article
© 2014 Lee et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.leads to lipoid proteinosis, an autosomal recessive skin dis-
order [4]. Clinically and experimentally, angiogenesis is as-
sociated with tumor progression. High levels of ECM1
expression are detected in aggressive tumorigenic cancer
cell lines MDA-MB-435 and LCC15 [3], and in human
carcinomas, including those of the lung, prostate, colon
and breast, and especially in ductal breast carcinomas [5].
ECM1 expression is also correlated with poor prognosis
[6] and metastatic potential in cancer [5,7]. However,
mechanism(s) by which ECM1 may influence tumorigen-
esis are unclear.
Trastuzumab (Ttzm) is a monoclonal antibody that
binds to the target protein HER2 and may inhibit growth
of tumor cells that overexpress HER2 [8]. The antitu-
moral effect of Ttzm in breast cancer may involve sup-
pression of Akt and extracellular signal-regulated kinase
(ERK) signaling and of cell cycle regulators, includingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cipal treatment for HER2-positive breast cancer [10]. How-
ever, a significant proportion of HER2-positive tumors do
not respond to or eventually escapes from Ttzm [11]. Ttzm
resistance is associated with high levels of EGF signaling
activity [12] and interactions of HER2 with other receptors,
including HER3 and insulin-like growth factor 1 receptor
[13]. In some patients, elevated p27 expression [14], loss of
PTEN [15] and activation of phosphatidylinositol 3-kinase
signaling [16] are related to Ttzm resistance. In Jimt-1 cells,
mucin 4 (MUC4), by masking HER2, may disrupt binding
between HER2 and Ttzm and thereby inhibit the action of
Ttzm [17]. The accumulation of HER2 extracellular do-
main fragments in serum through shedding of HER2 is
reported to induce Ttzm resistance [18]. Cellular pro-
cesses, including glucose metabolism [19] and epithelial-
to-mesenchymal transition (EMT) [20], may contribute
as well.
In this study, we investigated the involvement of
ECM1 in development of Ttzm resistance. We estab-
lished Ttzm-resistant BT-474 (BT-474 TR) cells through
in vivo xenograft systems. We compared the full spectra
of proteins expressed and proteins secreted (the prote-
ome and secretome) of BT-474 TR cells with those of
control cells using two-dimensional digest (ChemDigest/
Trypsin) liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) and identified ECM1 as a Ttzm resist-
ance biomarker protein. Our findings showed that ECM1
may influence cell proliferation and Ttzm resistance in hu-
man breast cancer cells through augmentation of EGF
signaling.
Methods
Cell lines, antibodies, reagents and plasmids
Human breast carcinoma cell lines BT-474, MCF-7,
SKBR3, MDA-MB-231, T47D, MDA-MB-468 were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). All cells were cultured
according to the recommended conditions of ATCC.
Mitogen-activated protein kinase kinase (MEK) inhibitor
U0126 was obtained from Calbiochem (San Diego, CA,
USA). Ttzm was obtained from Roche Applied Science
(Indianapolis, IN, USA). Cycloheximide was obtained
from Sigma-Aldrich (St Louis, MO, USA). Recombinant
ECM1 and matrix metalloproteinase 9 (MMP9) were
purchased from R&D Systems (Minneapolis, MN, USA).
A plasmid containing human ECM1 was made by PCR
cloning from pCMV-AC-ECM1 (OriGene Technologies,
Rockville, MD, USA), and cloning the gene into the
pBABE-puro vector using BamHI and EcoRI restriction
enzymes. The ECM1 short-hairpin RNA (shRNA) was
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The MMP9-Luc plasmid was kindly provided
by Professor Jan Šmarda (Masaryk University, Brno,Czech Republic). Wild-type (ERK1-WT) was donated by
Dr. Su-Jae Lee (Hanyang University, Seoul, Korea).
Tumor xenografts
Four-week-old female BALB/c nude mice (ORIENT BIO,
Gyeonggi-do, Korea) were implanted with 0.72-mg, 60-
day release, 17β-estradiol pellets (Innovative Research,
Sarasota, FL, USA). Twenty million BT-474 WT cells sus-
pended in 200 μl of phosphate-buffered saline (PBS) were
injected subcutaneously into the flank of the mice via a
22-gauge, 1.5-inch needle the next day. When the tumors
reached a volume of greater than 250 mm3, 20 mg/kg
Ttzm diluted in sterile PBS was injected into the mice by
intraperitoneal injection every 3 days. The tumor volume
was calculated by using the following formula: Volume
(mm3) =Width2 × Length/2. We established BT-474 TR
cells according to a previously described method [12]. The
experiments were approved by the Hanyang University In-
stitutional Animal Care and Use Committee, headed by
Doo-Jin Park, MD, PhD, with (approval HY-IACUC-13-
025). The committee strictly follows internationally recog-
nized guidelines.
Western blot analysis
SDS-PAGE and immunoblotting were performed accord-
ing to a standard procedure. ECM1, HER3, phosphory-
lated ERK (p-ERK), ERK, actin, MUC1 and galectin-3
antibodies were obtained from Santa Cruz Biotechnology.
c-Raf, p-c-Raf, MEK, p-MEK, Akt, p-Akt antibodies were
obtained from Cell Signaling Technology (Danvers, MA,
USA). Epidermal growth factor receptor (EGFR) antibody
was obtained from Abcam (Cambridge, UK). HER2 anti-
body was obtained from Thermo Scientific (Waltham,
MA, USA).
Proliferation and viability assays
Thirty thousand cells were seeded into each well of 12-
well plates. Cells were trypsinized and counted using a
hemocytometer at 24, 48 and 72 hours after seeding. For
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assays, cells were seeded in 96-well plates
at 5 × 103 cells per well, exposed to indicated antibodies
and incubated for 48 or 72 hours. Cell viability was
assessed by adding 20 μl of 10 mg/ml MTT (Sigma-
Aldrich) to 100 μl of culture medium, and incubating
for 3 hours. The medium was removed, formazan was
dissolved in dimethyl sulfoxide, and the optical density
was measured at 590 nm using a Multiskan EX (Thermo
Scientific).
Two-dimensional digest LCMS/MS and data analysis
The proteomes and secretomes from BT-474 TR and
BT-474 WT cells were analyzed as described previ-
ously [21].
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Cells were harvested with 0.25% trypsin/ethylenedi-
aminetetraacetic acid and washed once with PBS. The
cells were fixed in 100% ice-cold methanol for 24 hours
at −20°C. Fixed cells were incubated with 25 μg/ml pro-
pidium iodide in PBS and 1 mg/ml RNase in PBS for
30 minutes at 4°C. Cell cycle analyses were performed
on a fluorescence-activated cell sorter (BD Biosciences,
Franklin Lakes, NJ, USA).
Real-time quantitative PCR
cDNA was synthesized from 5 μg of total RNA from
each sample using the GeneAmp RNA PCR Core Kit
(Applied Biosystems, Foster City, CA, USA). The cDNA
were amplified with KAPA SYBR FAST Universal qPCR
kit (Kapa Biosystems, Wilmington, MA, USA) using the
following primers (Additional file 1: Table S1). The
quantitative RT-PCR (RT-qPCR) experiments were per-
formed using a Thermal Cycler Dice Real Time System
TP850 (Takara Bio, Otsu, Japan).
Immunoprecipitation
One-milligram samples of cell lysates were precleared by
adding 30 μl of Protein A Sepharose (Invitrogen, Grand
Island, NY, USA) for 2 hours at 4°C. After centrifuga-
tion, the supernatants were incubated with either pri-
mary antibodies or normal immunoglobulin G (IgG)
overnight at 4°C. Protein A or G Sepharose (30 μl), se-
lected according to primary antibody, was added and in-
cubated for 3 hours at 4°C. After centrifugation, the
pellet was washed three times with cell lysis buffer con-
taining 1 mM phenylmethylsulfonyl fluoride. Immuno-
precipitates were resolved by SDS-PAGE and analyzed
by Western blotting.
Fluorescence resonance energy transfer–based MMP2/9
activity assay
To detect MMP2/9 activity, peptides cleaved specifically
by MMP2/9 and linked to an activatable fluorescent mo-
lecular probe (fluorescein isothiocyanate (FITC)-Gly-
Pro-Leu-Gly-Val-Arg-Gly-Dabcyl (FITC-GPLG/VRG-
Dabcyl)) were synthesized, based on MMP2/9-specific
peptide sequences presented in previous studies [22].
Cells were incubated in serum-free medium for 24 hours,
and the medium was then collected and reacted with
MMP2/9 substrate peptides for 20 hours in the dark.
Relative fluorescence units were determined at 480 to
620 nm using a Varioskan Flash multimode reader
(Thermo Scientific).
Dual luciferase assay
Cells seeded into 12-well plates were transfected with re-
porter constructs (1 μg) and pRL-CMV Renilla luciferase
(5 ng) as an internal control using Lipofectamine 2000reagent (Invitrogen). At 48 hours posttransfection, dual
luciferase assays were performed according to the manu-
facturer’s protocol (Promega, Madison, WI, USA).Cell surface protein biotinylation assay
Cells at 80% to 90% confluence in 100-mm dishes were
washed twice with ice-cold PBS and held for a further
15 minutes in ice-cold PBS. Biotinylation was performed
by incubating cells in PBS containing 0.5 mg/ml of EZ-
Link NHS-SS-Biotin (Thermo Scientific) for 30 minutes
at 4°C. Biotinylated cells were washed twice with PBS
and lysed. Lysates containing biotinylated proteins were
precipitated with streptavidin-conjugated agarose beads
(Invitrogen) and analyzed by Western blotting with the
indicated antibodies. To control for nonspecific labeling
of intracellular proteins, biotinylated cells were washed
with 100 mM glutathione (Sigma-Aldrich) for 20 minutes
at 4°C.Breast cancer patient serum collection
Serum samples from 20 HER2-positive breast cancer pa-
tients and accompanying data used in this study were
provided and approved by the Institutional Review
Board of the Asan Bio-Resource Center, Korea Biobank
Network (2012–0898). Informed consent was obtained
from each participant before surgery, and samples were
anonymized. All samples were stored in liquid nitrogen.Immunocytochemistry
Cells were washed with PBS, fixed with 4% paraformal-
dehyde and permeabilized with 0.1% Triton X-100 for
15 minutes. Fixed samples were blocked with 3% skim
milk in PBS for 1 hour, followed by incubation with pri-
mary antibody diluted in 1% skim milk in PBS for 1 hour.
After being washed with PBS, the samples were treated
with the anti-mouse IgG Cy3 or anti-rabbit IgG Oregon
Green. For DNA staining, cells were incubated with
Hoechst 33342 dye (1 μg/ml) for an additional 10 mi-
nutes. Immunofluorescence was monitored with an
Olympus upright fluorescence microscope (BX50F;
Olympus America, Center Valley, PA, USA).Statistical analysis
All data represent the results of at least three independent
experiments. The data are presented as mean values ± SD.
Experimental and control data were compared using Stu-
dent’s t-test. A value of P < 0.05 was considered statistically
significant.Supplementary materials and methods
Additional supplementary materials and methods can be
found in Additional file 1.
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ECM1 is highly expressed in Ttzm-resistant BT-474 cells
and confers Ttzm resistance
TR clones were established by transplanting HER2-
overexpressing breast cancer cells into nude mice and
treating the xenograft-bearing mice with Ttzm (Additional
file 2: Figure S1A). The BT-474 clones selected through
Ttzm treatment expressed resistance to Ttzm (Additional
file 2: Figure S1B) in vitro, and the rate of BT-474 TR cell
proliferation was increased as compared to parental BT-
474 cells (Additional file 2: Figure S1C). The BT-474 TR
cells displayed a smaller G1 fraction and increased S
fraction as compared to parental BT-474 cells (Additional
file 2: Figure S1D), indicating more rapid cell cycle pro-
gression in BT-474 TR cells.
Proteome and secretome analyses show exceptional
power in identifying proteins and in tracing the complex
circuitry of signals involved in tumor progression [23].
Using LC-MS/MS analysis, we identified several proteins
upregulated in BT-474 TR cells as compared to BT-474
WT cells (Table 1). ECM1 expression correlates adversely
with patient outcome in several types of cancer [5], and
ECM1 was expressed at relatively high levels in BT-474
TR cells, at both the mRNA and protein levels (Additional
file 2: Figures S1E and S1F). We evaluated the relationship
of ECM1 expression to Ttzm resistance in breast cancer
cells using cytotoxicity as a marker of the drug’s effec-
tiveness. Cotreatment with recombinant human ECM1
(rhECM1) and Ttzm reduced the antiproliferative effect of
Ttzm in BT-474 cells (Figure 1A, left). Conversely, ECM1
knockdown augmented Ttzm-induced cytotoxicity in BT-
474 TR cells (Figure 1A, right).
In addition, direct treatment of cells with anti-ECM1
antibodies not only augmented Ttzm-induced cytotoxicity
but also inhibited cell proliferation (Figure 1B). Use of two
types of anti-ECM1 antibodies (N17 and P19), each specific
for a different ECM1 epitope, strengthened the assumption
that the antibodies had directly inhibited ECM1 activity,
possibly by cross-linking the protein. The specificity of the
anti-ECM1 antibody effect was further supported by the
dose-dependent decrease in cell proliferation and increase
in cytotoxicity in cells treated with the antibodies and TtzmTable 1 Liquid chromatography-tandem mass spectrometry id
wild-type and trastuzumab-resistant BT-474 cellsa
UniProt accession number Protein name
Q16610 Extracellular matrix protein 1
P27797 Calreticulin
P07339 Cathepsin D
P00338 L-lactate dehydrogenase A chain
P04626 Receptor tyrosine protein kinase erbB-2
P17931 Galectin-3
aSI, Spectral index; TR, Trastuzumab-resistant; WT, Wild type.together (Additional file 2: Figure S2G). Moreover, anti-
ECM1 antibodies showed higher effectiveness in BT-474
TR cells, which overexpress ECM1.
Through manipulation of ECM1 expression, we found
that ECM1 may influence the suppressive effect of Ttzm
on tumorigenesis in a xenograft system (Figure 1C), and
sera from TR patients showed higher ECM1 levels than
sera from patients with Ttzm-sensitive tumors (Figure 1D
and Additional file 2: Figure S2H). These results imply
that the ECM1 in patient serum may directly influence
Ttzm sensitivity, consistent with the hypothesis that
stable ECM1 expression confers Ttzm resistance.
ECM1 promotes cell proliferation
As BT-474 TR cells had a rapid proliferation ratio com-
pared with parental BT-474 cells (Additional file 2:
Figures S1C and S1D), we hypothesized that ECM1 can
promote cell proliferation. To test the direct effect of
ECM1 on cell proliferation, we treated BT-474 and MCF-
7 cells with rhECM1. As determined by cell counting, this
treatment increased the cell proliferation rate in these
breast cancer cell lines (Figure 2A). To further test this ef-
fect, we overexpressed ECM1 in the BT-474 and MCF-7
cells and silenced ECM1 in BT-474 TR cells. Relative pro-
tein levels confirmed stable ECM1 expression (Additional
file 3: Figure S2A), and this overexpression of ECM1 en-
hanced cell proliferation in the cell lines (Figure 2A, bot-
tom). The knockdown of ECM1 by treatment with shRNA
and anti-ECM1 antibodies in BT-474 TR cells reduced cell
proliferation (Figure 2A, right). The anti-ECM1 antibodies
also inhibited cell proliferation in other breast cancer cell
lines (Additional file 3: Figure S2B). The MDA-MB-231
cell line, which overexpresses ECM1, showed especially
high sensitivity to anti-ECM1 antibodies. To explore the
mechanism for the cell-proliferative effect of ECM1, we
analyzed the interrelationship of ECM1 expression with
cell cycle progression. Cells overexpressing ECM1 showed
an increased fraction of cells in S phase with a corre-
sponding reduction of the fraction in G1 phase. Similarly,
ECM1 knockdown led to the accumulation of cells in G1
phase with a decrease in the S-phase fraction (Figure 2B).
Thus, ECM1 may positively regulate cell proliferation byentification of proteins differentially secreted by BT-474
Gene name SIWT SITR Log2 (SITR/SIWT)
ECM1 0.0762 153.8420 8.94
CALR 8.5510 32.8933 1.3853
CTSD 27.7801 168.2733 2.0520
LDHA 55.1457 171.2111 1.0651
ERBB2 12.7955 33.2680 0.7694
LGALS3 0.4470 9.4270 3.7263
Figure 1 (See legend on next page.)
Lee et al. Breast Cancer Research  (2014) 16:479 Page 5 of 17
(See figure on previous page.)
Figure 1 Extracellular matrix protein 1 confers resistance toward trastuzumab. (A) Cells were seeded with Matrigel and treated with trastuzumab
(Ttzm; 20 μg/ml) and recombinant human ECM1 (rhECM1; 200 ng/ml). The number of colonies 20 μm or greater in diameter was counted at 12 days
(*P< 0.05, **P< 0.005). WT, Wild type. (B) At 24 hours after cell seeding, each cell line was treated with anti-ECM1 antibody (5 μg/ml) and Ttzm (20 μg/ml)
in fresh medium. After a further 48 hours, cell viability was analyzed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (*P< 0.05,
**P< 0.005, ***P< 0.0005). (C) BT-474 vector and ECM1 cells and BT-474 Ttzm-resistant (TR) control (Cont) short-hairpin (shRNA; shC) and ECM1 shRNA (shE)
cells were passaged by subcutaneous injection into the lower flank of each mouse. When the tumor size increased up to 250 mm3, Ttzm at 20 mg/kg was
administered to each mouse by intraperitoneal injection twice per week (n= 5 or 6 for each group). (D) Circulating levels of ECM1 in serum from TR breast
cancer patients were assessed by enzyme-linked immunosorbent assay (left) and Western blot analysis and compared with (right) corresponding data for
Ttzm-responsive patients (*P< 0.05).
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ECM1 on cell proliferation in vivo, we tested the relation-
ship of ECM1 expression to xenograft tumor formation in
BALB/c nude mice. In BT-474 cells overexpressing ECM1,
tumor formation efficiency was significantly increased,
whereas tumorigenic potential of the BT-474 TR cells was
significantly decreased after ECM1 silencing (Figure 2C).
Moreover, the Kaplan-Meier plots [24] constructed using
datasets from HER2-positive breast cancer patients dem-
onstrated a significant association of ECM1 expression
with poor outcome. Increasing ECM1 protein level pre-
dicted shorter distant metastasis-free survival in HER2-
positive breast cancer patients (Figure 2D, left). Indeed, we
found that high levels of ECM1 in serum were directly
and inversely related to overall survival in HER2-positive
breast cancer patients (Figure 2D, right). These data sug-
gested that ECM1 overexpression in patients may contrib-
ute to bad outcomes in human breast cancer.
ECM1 enhances EGF signaling
To investigate the mechanisms for improved proliferation
by ECM1, we checked the cell signaling pathway. Because
higher levels of phospho-ERK and phospho-EGFR, EGFR,
and HER3 expression in BT-474 TR cells (Additional file 3:
Figure S2C) and the level of ECM1 also correlated strongly
with levels of phosphorylated ERK in breast tumor tissues
(Additional file 3: Figure S2D), we hypothesized that
ECM1 may be related to EGFR-dependent ERK activation,
which can promote cell proliferation.
Because ECM1 is secreted extracellularly, we inhibited
ECM1 function with anti-ECM1 antibody which neutral-
ized the extracellular ECM1. We observed that treat-
ment of cells with anti-ECM1 antibody reduced EGFR
and ERK phosphorylation even after a treatment as brief
as 10 minutes (Figure 3A). These results indicated that
the activation of EGFR and ERK driven by ECM1 was
initiated by the events much earlier in the signaling cas-
cade. To confirm the effect of ECM1 on EGFR phos-
phorylation, we treated cells with both EGF and ECM1,
and we found that this cotreatment induced higher
levels of EGFR and ERK phosphorylation as compared
to treatment with EGF alone (Figure 3B). However, the
levels of phosphorylated EGFR and ERK proteins did
not change in cells treated in serum-free medium withrhECM1 alone (Additional file 3: Figure S2E). The
apparent augmentation of EGF response by ECM1 sug-
gested that ECM1 acted at the initiation of EGFR-
mediated signaling. On the basis of a report that ECM1
can physically associate with proteins bearing an EGF
domain [25], we tested the interaction between ECM1
and EGF in vitro, but we did not observe such an associ-
ation (Additional file 3: Figure S2F). However, as ECM1
is known to regulate cell signaling through association
with a cell surface receptor [26], we tested the inter-
action between ECM1 and EGFR. By coimmunoprecipi-
tation, ECM1 was found to interact physically with
EGFR (Figure 3C), and, by immunostaining and cell sur-
face biotinylation, ECM1 was detected at the cell surface
(Figure 3D). On the basis of these results, we concluded
that ECM1 may influence EGFR signaling through direct
interaction with the receptor protein.
ECM1 upregulates EGFR and HER3 expression
Although we previously showed that ECM1 enhanced
EGF-dependent activation of EGFR (Figure 3), we needed
to check the effect of ECM1 on EGFR and HER3 expres-
sion because we found that EGFR and HER3 expression
were increased in BT-474 TR cells compared with parental
BT-474 cells (Additional file 3: Figure S2C). We first
treated BT-474 and MCF-7 cells with rhECM1 for
48 hours (Figure 4A, right) and induced stable overexpres-
sion of ECM1 in the cells (Figure 4A, left). These treat-
ments increased levels of EGFR, HER3 and phospho-ERK,
proteins that were also upregulated in BT-474 TR cells.
Conversely, knockdown of ECM1 in BT-474 TR cells
reduced phospho-ERK levels. Consistent with these find-
ings, treatment with anti-ECM1 antibodies (two different
clones: N17 and P19) for 48 hours reduced expression of
EGFR, HER3 and phospho-ERK in BT-474 TR cells
(Figure 4A, middle).
Although EGFR mRNA levels did not differ significantly
between BT-474 WT and BT-474 TR cells, HER3 mRNA
levels were increased in BT-474 TR cells and cells overex-
pressing ECM1, whereas EMC1 silencing decreased the
HER3 mRNA level (Figure 4B). The level of HER3 mRNA
was similarly increased in ECM1-overexpressing MCF-7
cells (Additional file 4: Figure S3A). These results sug-
gested that ECM1 augmented HER3 expression at the
Figure 2 Relationship of extracellular matrix protein 1 level to breast cancer cell proliferation. (A) Each cell line was treated with 200 ng/
ml recombinant human extracellular matrix protein 1 (rhECM1) or 5 μg/ml anti-ECM1 antibodies, and cells were counted with a hemocytometer
over the course of 3 days (*P < 0.05, **P < 0.005). Cont, Control; shC, Control short-hairpin RNA; shE/shECM1, Short-hairpin extracellular matrix
protein 1 RNA; TR, Trastuzumab-resistant; Vec, Vector. (B) Cell cycles were analyzed by flow cytometry (*P < 0.05, **P < 0.005). (C) Each cell line
was passaged by subcutaneous injection into the lower flank of each mouse. Tumor volume was measured every 3 days (n = 5 or 6 for each
group). (D) Kaplan-Meier analyses for recurrence-free survival, overall survival and distant metastasis-free survival in the HER2-positive breast cancer
patients. Data were obtained from the Kaplan-Meier Plotter Breast Cancer database [24]. Overall survival data from breast cancer patients were
stratified by ECM1 levels in HER2-positive patient sera (n = 27).
Lee et al. Breast Cancer Research  (2014) 16:479 Page 7 of 17
Figure 3 (See legend on next page.)
Lee et al. Breast Cancer Research  (2014) 16:479 Page 8 of 17
(See figure on previous page.)
Figure 3 Extracellular matrix protein 1 augments epidermal growth factor signaling. (A) At 24 hours after seeding, BT-474 trastuzumab-
resistant (TR) and BT-474 extracellular matrix protein 1 (ECM1)-expressing cells were treated with anti-ECM1 antibodies (ab; 5 μg/ml). Ten minutes
later, cell lysates were analyzed on Western blots. (B) After serum starvation for 24 hours, cells were treated with recombinant human extracellular
matrix protein 1 (rhECM1; 200 ng/ml) and epidermal growth factor (EGF; 10 ng/ml). Cell lysates were prepared at the indicated time points and
analyzed on Western blots. (C) Total cell lysates were incubated with epidermal growth factor receptor (EGFR) antibodies overnight, and
immunoprecipitates (IP) were analyzed on Western blots. IgG, Immunoglobulin G; shC, Control short-hairpin RNA; shE, Extracellular matrix protein
1; Vec, Vector. (D) Cells were incubated with 0.5 mg/ml EZ-Link NHS-SS-Biotin for 30 minutes at 4°C. The biotinylated proteins were precipitated
by streptavidin, and the precipitates were analyzed on Western blots (IB) using ECM1 antibody (left). Cell surface labeling of ECM1 was conducted
by immunostaining without permeabilization (right). Extracellular signal-regulated kinase (ERK) was used as an endogenous negative control
protein. DIC, Differential Interference Contrast; GSH, Glutathione.
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not alter HER3 promoter activity as determined by lucif-
erase reporter assays in BT-474 cells (Additional file 4:
Figure S3B). The logical next step, then, was to determine
the effect of ECM1 on EGFR and HER3 protein stabilities.
In BT-474 cells, ECM1 stabilized both EGFR and HER3
proteins (Figure 4C). Taken together, these findings
indicated that ECM1 influenced EGFR expression at a
posttranslational level and HER3 expression at both tran-
scriptional and posttranslational levels. The increase in cell
proliferation related to ECM1 expression may involve both
stabilization of EGFR and HER3 proteins and upregulation
of HER3 transcription.
EGFR and HER3 are stabilized by ECM1 through galectin-3/
MUC1
Protein stabilization, shown as an increase in protein
half-life, frequently represents a physical interaction be-
tween protein molecules in the course of functional ac-
tivity. The signaling and trafficking activities of EGFR,
for example, involve interaction with mucin 1 (MUC1)
[27]. Galectin-3, a β-galactosidase-binding secretory pro-
tein, facilitates this interaction and may thereby stabilize
the other two proteins. Galectin-3 interacts with MUC1
and regulates MUC1 expression and function in cancer
cells [27,28]. Galectin-3 secretion was increased in BT-
474 TR cells (Table 1). On the basis of these obser-
vations, we examined the secretion of galectin-3 and
expression of MUC1 in BT-474 TR cells. Galectin-3 pro-
tein in the conditioned media and MUC1 protein content
were increased in BT-474 TR cells, whereas the intracellu-
lar level of galectin-3 did not change with acquisition of
Ttzm resistance (Additional file 4: Figure S3D). To test
whether galectin-3 secreted into the culture medium was
related to ECM1 action, we treated cultured breast cancer
cells with rhECM1. Interestingly, the galectin-3 level in-
creased in the medium, as did the level of MUC1 expres-
sion in the cells (Figure 5A, right). Similarly, ECM1
overexpression increased the levels of galectin-3 and
MUC1 expression (Figure 5A, left). Conversely, ECM1
knockdown and anti-ECM1 antibody treatments reduced
the levels of galectin-3 and MUC1 expression in the BT-
474 TR cells (Figure 5A, middle). Although ECM1 levelsinfluenced MUC1 protein expression, changes in ECM1
did not influence levels of MUC1 mRNA (Additional file 4:
Figure S3E). These results suggested that the ECM1-
related increase in galectin-3 secretion may upregulate
MUC1 expression by posttranscriptional mechanisms.
To test the dependence of ECM1-related changes in
EGFR and HER3 expression on galectin-3 and MUC1,
we performed knockdown using small interfering RNA
(Figure 5B). The knockdown of galectin-3 or MUC1 in BT-
474 TR cells resulted in decreased levels of EGFR, HER3
and phospho-ERK proteins. Interestingly, galectin-3 knock-
down reduced MUC1 expression, but MUC1 knockdown
did not affect the galectin-3 level, indicating that galectin-3
acts upstream of MUC1 expression. MUC1 is known to ac-
tivate ERK signaling through interaction with EGFR pro-
teins [29] and to suppress EGFR degradation and facilitate
EGFR trafficking [30]. To investigate interactions of EGFR
with MUC1, as well as of HER3 with MUC1, that could po-
tentially stabilize EGFR or HER3, we coimmunoprecipi-
tated these proteins in BT-474 cells. Interactions between
MUC1 and EGFR/HER3 were increased in BT-474 TR cells
(Additional file 4: Figure S3F). Likewise, rhECM1 treatment
and ECM1 overexpression enhanced interactions between
MUC1 and EGFR/HER3 in BT-474 cells (Figures 5C and
5D, left), whereas knockdown of ECM1 in BT-474 TR cells
reduced these interactions (Figure 5D, right). Colocaliza-
tions of EGFR-MUC1 and of HER3-MUC1 were also in-
creased in TR cells by ECM1 expression (Additional file 4:
Figure S3G). Thus, ECM1 may stabilize EGFR and HER3
by promoting interactions of these proteins with galectin-3
and MUC1.
ECM1 promotes MMP9 expression
The ECM1-dependent increase in galectin-3 secretion
by cultured cells implied the intervention of a factor up-
stream, such as MMP2/9, which acts on galectin-3 as a
substrate in developmental processes [31]. Mutation at
the MMP9 cleavage site in galectin-3 reduces extracellu-
lar galectin-3 and also suppresses tumorigenicity of
breast cancer cells [32]. Using zymography and a fluor-
escence resonance energy transfer (FRET)-based assay
for MMP2 and MMP9 activities, we measured higher
MMP9 activity in BT-474 TR cells than in BT-474 WT
Figure 4 (See legend on next page.)
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Figure 4 Extracellular matrix protein 1 activates extracellular signal-regulated kinase signaling by upregulating epidermal growth
factor receptor and HER3. (A) At 24 hours after cell seeding, each cell line was treated with recombinant human extracellular matrix protein 1
(rhECM1; 200 ng/ml) or anti-ECM1 antibodies (5 μg/ml) and further incubated for 48 hours. Cells lysates were then analyzed by Western blotting.
Cont, Control; ERK, Extracellular signal-regulated kinase; shC, Control short-hairpin RNA; shE, Extracellular matrix protein 1 short-hairpin RNA; TR,
Trastuzumab-resistant; Vec, Vector; WT, Wild type. (B) Epidermal growth factor receptor (EGFR) and HER3 mRNA levels were determined by
real-time PCR using primers specific for EGFR and HER3 (**P < 0.005, ***P < 0.0005). (C) Each cell line was treated with 100 μg/ml cycloheximide
(CHX). Cell lysates were prepared at the indicated time points and analyzed on Western blots. Band intensities on the blots were quantified using
1DScan software (Scanalytics, Milwaukee, WI) and plotted versus time as the ratios of EGFR/actin and HER3/actin intensities (*P < 0.05).
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of ECM1 reduced MMP9 activity in BT-474 TR cells, and
ECM1 overexpression increased MMP9 activity in BT-474
and MCF-7 cells (Figure 6A). Although our FRET assays
employed an MMP substrate susceptible to both MMP2
and MMP9, we found that modulation of ECM1 resulted
in increased MMP9 activity, whereas MMP2 activity
remained constant as determined by gelatin zymography
assay (Additional file 5: Figure S4B). In a cell-free system,
changes in ECM1 expression did not influence MMP9 ac-
tivity (Additional file 5: Figure S4C). In BT-474 TR cells,
however, the MMP9 mRNA level was higher than in
control cells (Additional file 5: Figure S4D), and, in both
BT-474 and MCF-7 cells, changes in ECM1 expression
correlated with changes in MMP9 transcript levels
(Figure 6B, left). In accord with previous results, MMP9
promoter activity increased following the acquisition of
the TR phenotype and increases in ECM1 expression in
BT-474 and MCF-7 cells (Figure 6B, right). These results
may mean that ECM1 regulates MMP9 expression at the
transcriptional level. The transcription factor Sp1 is re-
ported to bind at the MMP9 promoter upon ERK activa-
tion [33]; hence, we speculated that ERK might influence
MMP9 transcription through Sp1 activation. Seeking to
link ECM1 activity with MMP9 transcription, we investi-
gated the regulatory signaling of MMP9 expression. In BT-
474 cells, we found that ERK overexpression induced
MMP9 transcription (Additional file 5: Figure S4E) and
that treatment with U0126, a specific inhibitor of MEK, re-
duced MMP9 transcription (Additional file 5: Figure S4F).
These results may indicate that ERK activates Sp1, which
in turn regulates MMP9 transcription. To further confirm
MMP9 as a mediator of ECM1-dependent effects, we
treated breast cancer cells with recombinant human
MMP9 (rhMMP9). The results of this treatment included
higher levels of galectin-3 in supernatant media, as well
as higher levels of MUC1, EGFR and HER3 proteins.
Interestingly, levels of phosphorylated ERK also in-
creased (Figure 6C), and Ttzm-treated BT-474 cells
were rescued from cytotoxicity by the rhMMP9 treat-
ment (Additional file 5: Figure S4G). These findings
suggested that ECM1 may regulate cellular events through
modulation of MMP9 transcription.Discussion
The present study demonstrates that ECM1 may regulate
both cancer cell proliferation and Ttzm resistance through
interaction with EGF signaling. ECM1 was shown to asso-
ciate directly with EGFR, and EGF-dependent EGFR and
ERK activation followed thereafter. EGF was in turn
shown to activate ERK signaling at the level of transcrip-
tion, through activation of the transcription factor Sp1
and MMP9 expression proceeded downstream of these
events. Galectin-3 cleavage, dependent on MMP9 upregu-
lation, facilitated formation of a galectin-3/MUC1/EGFR
complex. This cascade of signaling events led to EGFR
and HER3 protein stabilization, as well as to ERK activa-
tion in breast cancer cells (schematically illustrated in
Figure 6D).
ECM1-dependent upregulation of the EGF response
could drive the acquisition of Ttzm resistance, as previ-
ously suggested [12]. ECM1 is known to interact with the
EGF domain on other proteins, such as perlecan [25], and
perlecan may induce heparin-binding growth factor re-
sponses, including the fibroblast growth factor 2 (FGF2)
response, and thereby promote tumor growth [34]. In-
deed, ECM1 and perlecan interact during development
and in pathological events, including tumor progression.
In testing the effect of ECM1 on FGF2-mediated re-
sponses (Additional file 3: Figure S2G), we found no fur-
ther enhancement of FGF2 response in cells cotreated
with both proteins as compared to FGF2 alone. However,
although ECM1 showed no interaction with FGF2 signal-
ing, ECM1 has been shown to associate with various other
cell surface receptors [26], such as the interleukin 2 re-
ceptor. Moreover, various proteins that bind with EGFR
also regulate the activation and trafficking of EGFR
[30,35]. It was recently reported that epidermal growth
factor-containing fibulin-like extracellular matrix protein
1 (EFEMP1) binds to EGFR and attenuates EGFR signal-
ing [36]. ECM1 may interrupt binding of inhibitory pro-
tein like EFEMP1. In the present study, we demonstrated
that ECM1 may interact physically with EGFR and en-
hance EGF signaling. Interactions between ECM1 and
extracellular matrix components such as laminin, collagen
and fibronectin may enhance binding of these com-
ponents [37]. We did not focus on these interactions,
Figure 5 Extracellular matrix protein 1 stabilizes epidermal growth factor receptor and HER3 proteins through galectin-3/mucin 1. (A) Lysates
from each cell line were analyzed by Western blotting. shC, Control short-hairpin RNA; shE, Extracellular matrix protein 1 short-hairpin RNA; Vec, Vector; WT,
Wild type. (B) At 24 hours after seeding, BT-474 trastuzumab-resistant (TR) cells were transfected with each small interfering RNA (siRNA: siC, Control; sigal-3,
galectin-3; siMUC1, mucin 1), incubated further for 48 hours and analyzed on Western blots. (C) At 24 hours after seeding, cells were treated with recombinant
human extracellular matrix protein 1 (rhECM1; 200 ng/ml) and incubated further for 48 hours. Cell lysates were then incubated with mucin 1 (MUC1),
epidermal growth factor receptor (EGFR) and HER3 antibodies overnight. Immunoprecipitates (IP) were analyzed on Western blots. IgG, Immunoglobulin G.
(D) Total cell lysates were incubated with MUC1, EGFR and HER3 antibodies overnight, and immunoprecipitates were then analyzed on Western blots.
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Figure 6 Extracellular matrix protein 1 induces matrix metalloproteinase 9 transcription. (A) At 24 hours after seeding, cells were
incubated with serum-free medium for a further 24 hours. Supernatant medium from each cell line was reacted with matrix metalloproteinase 9
(MMP9) substrate, and relative fluorescence units were determined at 480 to 620 nm. Cont, Control; shC, Control short-hairpin RNA; shE, Extracellular
matrix protein 1 short-hairpin RNA; TR, Trastuzumab-resistant; Vec, Vector. (B) MMP9 mRNA levels were determined by real-time PCR using primers
specific for MMP9 (*P < 0.05). Each cell line was transfected with an MMP9 promoter luciferase reporter construct. After 48 hours, cells were harvested,
and the lysates were analyzed by dual-luciferase assay (*P< 0.05, ***P< 0.0005). (C) At 24 hours after seeding, each cell line was treated with recombinant
human MMP9 (rhMMP9; 20 ng/ml), incubated further for 48 hours, and lysates from each cell were analyzed by Western blotting. EGFR, Epidermal growth
factor receptor; ERK, Extracellular signal-regulated kinase; MUC1, Mucin 1; WT, Wild type. (D) Schematic model showing the role of extracellular matrix
protein 1 (ECM1) in cell signaling. EGF, Epidermal growth factor.
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naling that occurred through association with EGFR in a
brief interaction with the cell.
In BT-474 TR cells, which overexpress ECM1, we
showed that expression of EGFR and HER3 were in-
creased as compared with parental BT-474 cells. An in-
crease in expression or activation of EGFR proteins iscorrelated with Ttzm resistance, and Ttzm resistance has
been shown to depend on EGFR expression [12]. Also, in-
creased interaction between HER2 and HER3 promotes
acquisition of Ttzm resistance [13], and HER3 upregula-
tion may compensate for inhibition of the HER2 tyrosine
kinase [38]. On the basis of our data (Figure 2D), we found
that patients with highly positive ECM1/HER2 tumors
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ECM1 may interact with EGFR family receptors that inter-
act with HER2 to attenuate therapeutic action by Ttzm.
Also noteworthy is that galectin-3/MUC1 interactions
influenced the stability of EGFR and HER3 proteins. Inter-
action of galectin-3 and MUC1 regulates the expression
and function of MUC1 [27,28], and galectin-3 facilitates
an interaction between MUC1 and EGFR [27] that pro-
motes EGFR activation. Galectin-3 is reported to regulate
intracellular trafficking of EGFR in keratinocytes and to
promote cell migration [39]. MUC1 also regulates EGFR
trafficking and may inhibit EGFR degradation [30]. Ac-
cordingly, treatment of cancer cells with anti-MUC1 anti-
body inhibits EGFR signaling [40]. MUC1 activity is also
known to contribute to Ttzm resistance [41], and a high
circulating level of galectin-3 in patient serum is related to
tumor progression [42].
In the present study, our secretome analysis revealed in-
creased secretion of galectin-3 into the culture medium by
TR cells (Table 1). We showed that ECM1 expression pro-
moted EGFR and HER3 stabilities by posttranslational ac-
tivities involving MUC1 and that ECM1 regulated HER3 at
the mRNA level. We also monitored microRNA-205 (miR-
205) expression in ECM1-expressing cells (Additional file 4:
Figure S3C). miR-205 is known to inhibit HER3 expression
through interaction with HER3 mRNA [43]. However, we
found no evidence that ECM1 affected miR-205 levels. In
addition, it seems plausible, based on our findings, that
the unfavorable prognosis associated with highly MUC1/
HER2-positive breast tumors (data not shown; see [24])
may be attributable to ECM1-mediated upregulation of
MUC1.
Circulating serum galectin-3 may increase through
MMP9-dependent cleavage of membrane-bound galectin-3
[32], and this cleavage of galectin-3 by MMP9 promotes
breast cancer angiogenesis and progression [44]. Although
ECM1 is reported to inhibit MMP9 activity [45], we did not
observe this effect of ECM1 (Additional file 5: Figure S4C).
Having shown that MMP9 mediated ECM1-dependent
cellular events (Figure 6), we investigated the mechanism
for ECM1-regulated MMP9 transcription. Indeed, the cor-
relation of ECM1 expression with MMP9 levels was shown
in a previous study [46], and, consistent with our results,
MMP9 has been demonstrated to regulate cell proliferation
through EGFR-mediated activation of ERK in Schwann cells
[47]. In addition, MMP9 acts as a sheddase of HER2 [48],
and an increase in circulating HER2 through shedding
may be an essential factor in development of resistance to
chemotherapy, including Ttzm resistance, in advanced
breast cancer [49]. In BT-474 TR cells in culture, we de-
tected higher extracellular HER2 levels than in the parent
line (Table 1), and we observed that rhMMP9 augmented
this effect (data not shown). Although we suggest that
the main mechanism by which ECM1 regulates Ttzmresistance is through an increase of EGFR/HER3 by the
activities of MMP9, we cannot rule out the possibility that
upregulation of MMP9 expression by ECM1 increases cir-
culating HER2 levels and that this source of HER2 con-
tributes to Ttzm resistance.
In addition, our finding that ECM1 upregulates MUC1
may inform future research into the signaling that initi-
ates and maintains malignant phenotype. MUC1 blocks
degradation and nuclear accumulation of β-catenin [50],
a protein with multiple regulatory functions that thus is
influential in tumor development, and MUC1 regulates
gene transcription by forming a complex with nuclear
factor κB [51]. Moreover, MUC1 promotes a metastatic
phenotype of cancer cells by inducing EMT and activat-
ing the ZEB1/miR-200c regulatory loop [52]. We suggest
that ECM1 may influence the EMT, and thus metastatic
potential, through regulation of MUC1 expression, in ac-
cordance with reported correlations of ECM1 expression
with metastasis in laryngeal carcinoma [53] and cholan-
giocarcinoma [46].
Conclusion
We found that ECM1 increased EGF-mediated signaling
through interaction with EGFR and subsequent activa-
tion of the ERK pathway. Our findings are clinically rele-
vant in identifying ECM1 as an unfavorable prognostic
marker in HER2-positive breast cancer.
Additional files
Additional file 1: Table S1. List of primers used in the study.
Supplementary materials and methods.
Additional file 2: Figure S1. ECM1 is over-expressed in Ttzm-resistant
BT-474 cells. (A) 17β-estradiol pellet was injected to 4-week-old BABL/c
nude mice and BT-474 WT cells were passaged in the mice by subcutaneous
injection of 2 × 107 cells into the lower flank of the mice. When the tumor
size grew to 250 mm3, 20 mg/kg Ttzm was injected into the mice by
intraperitoneal injection twice per week. NS-1 and NS-2, as control groups,
responded to Ttzm completely. (B) 5 × 104 cells were plated on soft agar
and Matrigel (Additional file 1: Supplementary materials and methods). In
Matrigel, Ttzm (20 μg/ml) was treated every 3 days. The number of colonies
(20 μm diameter) was counted at 12 days. The number of colonies is
quantified in right panels. Error bars represent mean ± SD of triplicate
experiments (*P < 0.05, **P < 0.005). (C) Cells were counted with a
hemocytometer over 3 days (*P < 0.05, **P < 0.005). (D) Cell cycles in BT-474
WT and BT-474 TR cells were analyzed using flow cytometry (*P < 0.05,
**P < 0.005). (E) mRNAs were analyzed by RT-PCR using primers specific for
ECM1 and GAPDH (Additional file 1: Supplementary materials and methods).
Secreted ECM1 was obtained from Trichloroacetic acid-precipitated cell
supernatant medium. Each cell lysate was analyzed by Western blotting
using ECM1- and actin-specific antibodies. (F) ECM1 mRNA levels were
determined by real-time PCR using primers specific for ECM1 (***P <
0.0005). (G) At 24 hours after cell seeding, each cell line was treated with
anti-ECM1 antibody (5 μg/ml) and Ttzm (20 μg/ml) in fresh medium. After a
further 48 hours, cell viability was analyzed using an MTT assay (*P < 0.05,
**P < 0.005, ***P < 0.0005). (H) Levels of ECM1 in serum from Ttzm-resistant
breast cancer patients were assessed Western blot analysis, and compared
with corresponding data for Ttzm-responsive patients.
Additional file 3: Figure S2. Functional role of ECM1 in cancer cell
proliferation. (A) Cells lysates were analyzed by Western blotting with the
Lee et al. Breast Cancer Research  (2014) 16:479 Page 15 of 17indicated antibodies. (B) Each cell line was treated with each anti-ECM1
antibody (see Methods) at 5 μg/ml. After a further 48 hours, cell viability
was analyzed using an MTT assay (*P < 0.05, **P < 0.005, ***P < 0.0005).
(C) Cell lysates were analyzed by Western blotting using indicated
antibodies. Anti-actin antibody was applied as a loading control. (D) Western
blot analysis shows levels of p-ERK and ECM1 proteins in primary tumor
lysates from breast cancer patients (n = 17). The positive relationship
between p-ERK and ECM1 expression levels is indicated (R2 = 0.6131).
(E) After serum starvation for 24 hours, cells were treated with rhECM1
(200 ng/ml) for 10 minutes. Cell lysates were analyzed by Western blotting
using indicated antibodies. (F) A mixture containing rhECM1 (500 ng) and
biotin-EGF (500 ng) was incubated with streptavidin-agarose beads
overnight and the immunoprecipitates were analyzed on Western blots.
(G) At 24 hours after cell seeding, BT-474 WT cells were treated with rhECM1
(200 ng/ml) and FGF2 (10 ng/ml). The cell lysates were obtained at the
indicated time points and subjected to Western blot analysis with indicated
antibodies.
Additional file 4: Figure S3. ECM1-dependent induction of EGFR/HER3
is mediated by MUC1. (A) EGFR and HER3 mRNA levels were determined
by real-time PCR using primers specific for EGFR and HER3 (**P < 0.005).
(B) Each cell was transfected with HER3 promoter luciferase reporter
constructs, harvested after 48 h and analyzed by dual-luciferase assay.
(C) Expression of miR-200c was assessed by RT-qPCR with a universal reverse
primer and forward primers specific for miR-200c using a TaqMan microRNA
assay kit (*P < 0.05) (Additional file 1: Supplementary materials and
methods). (D) Cell lysates were analyzed by Western blotting using
the indicated antibodies. (E) MUC1 mRNA levels were determined by
real-time PCR using primers specific for MUC1 (*P < 0.05). (F) Cell lysates
were incubated with MUC1, EGFR and HER3 antibodies overnight.
Immunoprecipitates were analyzed on Western blots. (G) Colocalizations of
MUC1 and EGFR/HER3 were monitored by immunostaining. Each cell was
fixed and stained with indicated antibodies and Hoechst dye for nuclear
staining.
Additional file 5: Figure S4. ERK-dependent regulation of MMP9
transcription by ECM1. (A) Supernatant medium from each cell line was
reacted with MMP9 substrate and relative fluorescence units were
determined at 480 to 620 nm. (B) Conditioned media from each cell
were collected, and gelatin zymography was performed. Arrows indicate
MMP2 and MMP9. Each bar graph represents the quantified intensity of
indicated cells, as assessed by gelatin zymography (*P < 0.05, **P < 0.005)
(Additional file 1: Supplementary materials and methods). (C) Media
containing rhMMP9 and rhECM1 were reacted with MMP9 substrate.
Relative fluorescence units were determined at 480 to 620 nm. (D) MMP9
mRNA levels were determined by real-time PCR using primers specific for
MMP9 (*P < 0.05). Each cell line was transfected with an MMP9 promoter
luciferase reporter construct. After 48 h, cells were harvested and the
lysates were analyzed by dual-luciferase assay (**P < 0.005). (E) and (F)
Each cell was transfected with ERK1-WT constructs (E) and treated with
U0126 (F). MMP9 mRNA levels were determined by real-time PCR using
primers specific for MMP9 and MMP9 promoter activity was analyzed by
dual-luciferase assay (*P < 0.05, **P < 0.005). (G) At 24 hours after cell
seeding, each cell line was treated with rhMMP9 (10, 20 ng/ml) and Ttzm
(20 μg/ml) and incubated further for 48 hours. Cell viability was then
analyzed using an MTT assay (**P < 0.005).Abbreviations
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